The molecular pathogenesis of endometrial clear-cell carcinoma: unclear, uncertain and possibly heterogeneous

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60, 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv. Anat. Pathol.11, 117–142 (2004).
   PubMed Web of Science ®Google Scholar
• Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol.24, 4783–4789 (2006).
   PubMed Web of Science ®Google Scholar
• Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int. J. Clin. Exp. Pathol.2, 411–432 (2009).
   PubMed Web of Science ®Google Scholar
• Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol.32, 569–577 (2001).
   PubMed Web of Science ®Google Scholar
• Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res.11, 6422–6430 (2005).
   PubMed Web of Science ®Google Scholar
• An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod. Pathol.17, 530–537 (2004).
   PubMed Web of Science ®Google Scholar
• DeLair D, Levine D, Bogomolniy F, Wethington S, Han G, Soslow RA. Molecular changes in endometrial clear cell carcinomas and carcinomas with clear cell features. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17–23 March 2012.
   Google Scholar
• Fadare O, Parkash V, Dupont WD et al. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an interobserver variability study. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17–23 March 2012.
   Google Scholar
• Wong OG, Huo Z, Siu MK et al. Hypermethylation of SOX2 promoter in endometrial carcinogenesis. Obstet. Gynecol. Int.2010, 682504 (2010).
   PubMedGoogle Scholar
• Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum. Pathol.29, 551–558 (1998).
   PubMed Web of Science ®Google Scholar
• Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet.40, 1153–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol.163, 2503–2512 (2003).
   PubMed Web of Science ®Google Scholar
• Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl. Immunohistochem. Mol. Morphol. (2012) (In Press).
   PubMedGoogle Scholar
• Roberts CW, Orkin SH. The SWI/SNF complex – chromatin and cancer. Nat. Rev. Cancer4, 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer11, 481–492 (2011).
   PubMed Web of Science ®Google Scholar
• Jones S, Wang TL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science330(6001), 228–231 (2010).
   PubMed Web of Science ®Google Scholar
• Wiegand KC, Shah SP, Al-Agha OM et al.ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med.363, 1532–1543 (2010).
   PubMed Web of Science ®Google Scholar
• Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol.224, 328–333 (2011).
   PubMed Web of Science ®Google Scholar
• Fadare O, Renshaw IL, Liang SX. Loss of BAF250a expression in endometrial clear cell carcinoma: an assessment of its frequency and clinicopathologic significance. Presented at: 101st Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17–23 March 2012.
   Google Scholar
• Guan B, Mao TL, Panuganti PK et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am. J. Surg. Pathol.35, 625–632 (2011).
   PubMed Web of Science ®Google Scholar
• Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J. Clin. Oncol.27, 4834–4838 (2009).
   PubMed Web of Science ®Google Scholar
• Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin. Thromb. Hemost.32, 24–32 (2006).
   PubMed Web of Science ®Google Scholar
• Fadare O, Renshaw IL, Liang SX. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events. Int. J. Gynecol. Pathol.30, 252–261 (2011).
   PubMed Web of Science ®Google Scholar
• Lee L, Garrett L, Lee H, Oliva E, Horowitz N, Duska LR. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J. Reprod. Med.54, 133–138 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol.32(2), 304–315 (2008).
   PubMed Web of Science ®Google Scholar
• Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene27, 6920–6929 (2008).
   PubMed Web of Science ®Google Scholar
• Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol.153, 333–339 (1998).
   PubMed Web of Science ®Google Scholar
• Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet. Gynecol.100(6), 1290–1295 (2002).
   PubMed Web of Science ®Google Scholar
• Arai T, Watanabe J, Kawaguchi M et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int. J. Gynecol. Cancer16(1), 391–395 (2006).
   PubMedGoogle Scholar
• Singh M, Spoelstra NS, Jean A et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod. Pathol.21, 912–923 (2008).
   PubMed Web of Science ®Google Scholar
• Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role of ERM proteins in cell adhesion and migration. Cell Adh. Migr.1(5), 199–206 (2011).
   Google Scholar
• Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol. Cell92, 305–316 (2000).
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Wang D, Lele S, Frederick PJ, Pejovic T, Liu S. Claudin7 and moesin in endometrial adenocarcinoma; a retrospective study of 265 patients. BMC Res. Notes5(1), 65 (2012).
   PubMedGoogle Scholar
• Mhawech-Fauceglia P, Wang D, Syriac S et al. Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma. Gynecol. Oncol.124, 148–152 (2012).
   PubMed Web of Science ®Google Scholar
• Briese J, Schulte HM, Sajin M et al. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas. Virchows Arch.453(1), 89–96 (2008).
   PubMed Web of Science ®Google Scholar
• Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal.21, 196–211 (2009).
   PubMed Web of Science ®Google Scholar
• Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res.71, 6718–6727 (2011).
   PubMed Web of Science ®Google Scholar